Publications by authors named "C A Grove"
Background: Students' sense of school belonging is important for mental health, physical health, and academic performance. However, some students do not feel as though they belong in their schools. This study investigated Greek secondary school students' perspectives on practices that enhanced their sense of belonging during the COVID-19 pandemic.
View Article and Find Full Text PDFBackground: Children in out-of-home-care (OOHC) are a vulnerable population, typically with complex needs, however there is minimal research examining the behavioural presentations that lead to the increased use of acute emergency care by OOHC children.
Objective: This study aimed to describe differences in lifetime complexity factors identified during ambulance attendances between children with and without an identified history of OOHC. Further, this study aimed to describe whether having an identified history of being in OOHC was associated with increased utilisation of emergency care resources and increased likelihood of multiple ambulance attendances.
Article Synopsis
- Phenotypic data helps us understand how genomic variations affect living organisms and is vital for clinical applications like diagnosing diseases and developing treatments.
- The field of phenomics aims to unify and analyze the vast amounts of phenotypic data collected over time, but faces challenges due to inconsistent methods and vocabularies used to record this information.
- The Unified Phenotype Ontology (uPheno) framework offers a solution by providing a standardized system for organizing phenotype terms, allowing for better integration of data across different species and improving research on genotype-phenotype associations.
Purpose: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with -rearranged () acute leukemia. Here, we evaluated the activity of revumenib in individuals with relapsed/refractory (R/R) acute leukemia.
Methods: AUGMENT-101 is a phase I/II, open-label, dose-escalation and expansion study of revumenib conducted across 22 clinical sites in five countries (ClinicalTrials.